All In Biotech

Drug Trial Radar · NCT06136624

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,310 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,310

Planned (sponsor's estimate)

Start

Dec 31, 2023

Primary completion

Nov 30, 2028

Study completion Mar 29, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.

Conditions

  • Prostate Cancer Metastatic

Interventions

  • OpevesostatDrug

    Administered orally

  • Abiraterone acetateDrug

    Administered orally

  • EnzalutamideDrug

    Administered orally

  • HydrocortisoneDrug

    Administered orally or IM as a rescue medication

  • Fludrocortisone acetateDrug

    Administered orally

  • PrednisoneDrug

    Administered orally as a rescue medication

  • DexamethasoneDrug

    Administered orally as rescue medication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive ParticipantsTime frame: Up to ~54 months
  2. OS in AR LBD Mutation-Negative ParticipantsTime frame: Up to ~54 months

Locations

288 sites in 36 countries. Site status is shown where the registry gives one.

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040)

    Orange, California · Completed

  • Stanford Cancer Center ( Site 0036)

    Palo Alto, California · Recruiting

  • Kaiser Permanente Riverside Medical Center ( Site 0099)

    Riverside, California · Recruiting

  • Anschutz Cancer Pavilion ( Site 0046)

    Aurora, Colorado · Recruiting

  • University of Colorado Health - Highlands Ranch Hospital ( Site 0111)

    Highlands Ranch, Colorado · Recruiting

  • Colorado Clinical Research ( Site 0067)

    Lakewood, Colorado · Completed

  • University of Colorado Health - Lone Tree Medical Center ( Site 0112)

    Lone Tree, Colorado · Recruiting

  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0064)

    New Haven, Connecticut · Recruiting

  • Florida Cancer Specialists - South ( Site 7003)

    Fort Myers, Florida · Completed

  • Bruce W. Carter Veterans Affairs Medical Center ( Site 0082)

    Miami, Florida · Completed

  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051)

    Miami, Florida · Recruiting

  • University of Illinois at Chicago ( Site 0105)

    Chicago, Illinois · Recruiting

  • University of Chicago Medical Center ( Site 0045)

    Chicago, Illinois · Recruiting

  • University of Iowa ( Site 0047)

    Iowa City, Iowa · Completed

  • University of Kentucky Chandler Medical Center ( Site 0048)

    Lexington, Kentucky · Completed

  • Ochsner Clinic Foundation ( Site 0108)

    New Orleans, Louisiana · Completed

  • Baltimore Veterans Affairs Medical Center ( Site 0069)

    Baltimore, Maryland · Recruiting

  • Greenebaum Comprehensive Cancer Center ( Site 0049)

    Baltimore, Maryland · Recruiting

  • Henry Ford Hospital ( Site 0015)

    Detroit, Michigan · Completed

  • Avera Cancer Institute - Marshall ( Site 0122)

    Marshall, Minnesota · Recruiting

  • M Health Fairview Clinics and Surgery Center ( Site 0019)

    Minneapolis, Minnesota · Recruiting

  • Metro-Minnesota Community Clinical Oncology ( Site 0014)

    Saint Louis Park, Minnesota · Active not recruiting

  • Hattiesburg Clinic Hematology/Oncology ( Site 0120)

    Hattiesburg, Mississippi · Recruiting

  • Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062)

    St Louis, Missouri · Recruiting

  • University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095)

    Omaha, Nebraska · Recruiting

  • Comprehensive Cancer Centers of Nevada ( Site 0010)

    Las Vegas, Nevada · Recruiting

  • Atlantic Health System Morristown Medical Center ( Site 0115)

    Morristown, New Jersey · Recruiting

  • Rutgers Cancer Institute of New Jersey ( Site 0033)

    New Brunswick, New Jersey · Completed

  • James J. Peters VA Medical Center ( Site 0088)

    The Bronx, New York · Recruiting

  • University Hospitals Cleveland Medical Center ( Site 0043)

    Cleveland, Ohio · Recruiting

  • Oregon Health and Science University ( Site 0028)

    Portland, Oregon · Completed

  • VA Portland Health Care System ( Site 0058)

    Portland, Oregon · Recruiting

  • AHN Allegheny General Hospital ( Site 0001)

    Pittsburgh, Pennsylvania · Completed

  • Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083)

    Charleston, South Carolina · Completed

  • Avera Cancer Institute - Aberdeen ( Site 0123)

    Aberdeen, South Dakota · Recruiting

  • Avera Cancer Institute - Mitchell ( Site 0121)

    Mitchell, South Dakota · Recruiting

  • Avera Cancer Institute - Pierre ( Site 0118)

    Pierre, South Dakota · Recruiting

  • Avera Cancer Institute- Research ( Site 0094)

    Sioux Falls, South Dakota · Recruiting

  • Avera Cancer Institute - Yankton ( Site 0117)

    Yankton, South Dakota · Recruiting

  • SCRI Oncology Partners ( Site 7000)

    Nashville, Tennessee · Recruiting

Showing 40 of 288 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.